rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    LSTA
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      12 Health Care Stocks Moving In Wednesday's Intraday Session
      Nov 11BenzingaLSTA
      Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces MAR001 Reduces Triglycerides Without Worsening Glycemic Control in Phase 2b TYDAL-TIMI 78 Trial; Results Presented as AHA 2026 Late-Breaker and Published in The New England Jo
      Nov 9Yahoo FinanceLSTA
      Marea Therapeutics, a Subsidiary of Lisata Therapeutics, to Participate in Upcoming November Investor Conferences

      SOUTH SAN FRANCISCO, Calif. and LIBERTY CORNER, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Marea Therapeutics, Inc. (“Marea”), a subsidiary of Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”), a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced that management will participate in the following investor conferences: Guggenheim Healthcare Innovation ConferencePrese

      Nov 5Yahoo FinanceLSTA
      Lisata Therapeutics, Inc. (LSTA) Stock Price, News, Quote & History - Yahoo Finance

      Find the latest Lisata Therapeutics, Inc. (LSTA) stock quote, history, news and other vital information to help you with your stock trading and investing.

      Oct 21Yahoo FinanceLSTA
      Lisata Therapeutics Expands Board, Appoints Independent Director

      Detailed price information for Lisata Therapeutics Inc (LSTA-Q) from The Globe and Mail including charting and trades.

      Oct 15The Globe and MailLSTA
      Lisata adds biopharma finance veteran Jeffrey Farrow to board
      Oct 15Yahoo FinanceLSTA
      Lisata Therapeutics adds Jeffrey Farrow to board of directors
      Oct 14Investing.comLSTA
      Lisata Therapeutics Appoints Jeff Farrow to Board of Directors
      Oct 14Yahoo FinanceLSTA
      Lisata Therapeutics wins new US patent for pancreatic cancer drug
      Oct 8Yahoo FinanceLSTA
      Lisata Therapeutics receives patent for certepetide cancer treatment
      Oct 8Investing.comLSTA
      Lisata Therapeutics Announces New Method of Use Patent Granted for Certepetide in the Treatment of Pancreatic Cancer and Other Solid Tumors

      LIBERTY CORNER, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company, today announced that the United States Patent and Trademark Office (“USPTO”) has granted a new Method of Use patent for certepetide [U.S. Patent No. 12,751,991] for the treatment of pancreatic cancer and other solid tumors, expiring May 2041. The newly issued patent, titled “Methods for Treating Pancreatic Cancer and Other Solid Tu

      Oct 8Yahoo FinanceLSTA
      Marea Therapeutics doses first patient in MAR002 phase 2 trial
      Oct 5Investing.comLSTA
      Lisata subsidiary Marea treats first patient in MAR002 acromegaly trial
      Oct 5Yahoo FinanceLSTA
      Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly
      Oct 5Yahoo FinanceLSTA
      Lisata subsidiary Marea Therapeutics gets late-breaking slot at AHA Scientific Sessions

      Marea Therapeutics, a subsidiary of Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE), said data from the Phase 2b TYDAL study of its lead candidate MAR001 will be presented in a late-breaking science session at the American Heart Association Scientific Sessions 2026 in Chicago. MAR001 is an...

      Sep 24Yahoo FinanceLSTA
      Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces Upcoming Late-Breaking Presentation of MAR001 Clinical Data at the American Heart Association Scientific Sessions 2026

      Late-breaking presentation will highlight Phase 2b clinical data for MAR001, a potential first-in-class antibody targeting ANGPTL4 designed to lower triglycerides and improve metabolic functionSOUTH SAN FRANCISCO and LIBERTY CORNER, N.J., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Marea Therapeutics, Inc. (“Marea”), a subsidiary of Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”), a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-g

      Sep 24Yahoo FinanceLSTA
      Lisata Therapeutics (LSTA) Buys Marea and Signs $225M Financing. Is the Dilution Worth it?
      Sep 23Yahoo FinanceLSTA
      Lisata Therapeutics Acquires Marea, Refocuses on Cardioendocrine Portfolio

      Detailed price information for Lisata Therapeutics Inc (LSTA-Q) from The Globe and Mail including charting and trades.

      Sep 18The Globe and MailLSTA
      Nano Cap Lisata Therapeutics Bolsters Cardioendocrine Pipeline Strategy
      Sep 17BenzingaLSTA
      Lisata deal propels Marea’s drug pipeline to Wall Street

      Marea’s acquisition by Lisata, alongside a $225 million financing deal, will back development of a pair of medicines in mid-stage testing for cardiovascular and endocrine conditions.

      Sep 17Yahoo FinanceLSTA
      Lisata Therapeutics acquires Marea Therapeutics, secures $225 million private placement

      Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) has acquired Marea Therapeutics, a clinical-stage biotech developing next-generation medicines for cardioendocrine diseases. The companies also entered a private placement financing agreement expected to raise approximately $225 million in gross...

      Sep 17Yahoo FinanceLSTA
      Lisata Therapeutics acquires Marea, raises $225 million
      Sep 17Investing.comLSTA
      Lisata Therapeutics Announces Acquisition of Marea Therapeutics and $225 Million Concurrent Private Placement

      Combined company to focus on developing first-in-class next-generation medicines for cardioendocrine diseases Marea has multiple late-stage clinical product candidates: MAR001/005 for severe hypertriglyceridemia (sHTG) currently in Phase 2b and MAR002 for the treatment of acromegaly which is advancing to a Phase 2 study Concurrent financing of $225 million from leading life sciences investors and other institutional investors projected to fund operations into 2028 LIBERTY CORNER, N.J., Sept. 17,

      Sep 17Yahoo FinanceLSTA
      12 Health Care Stocks Moving In Friday's Intraday Session
      Aug 21BenzingaARCTHOWLJUNSLSTA

      This is the newest page. Registered accounts read further back.